|
||
| |||||||
|
Introduction: Colorectal cancer is a highly prevalent, with over 400,000 new patients diagnosed across the seven major markets each year. New drugs, such as irinotecan, oxaliplatin and capecitabine, have recently revolutionized chemotherapy for the disease. However, there still remains a high level of unmet need, which will only be partially satisfied by the relatively weak pipeline of developmental agents. As such, the colorectal cancer market represents a lucrative target for pharmaceutical manufacturers. Scope: * 220 interviews with oncologists and gastroenterologists across the seven major markets backed up by key opinion leader commentary. * In-depth analysis of current treatment patterns according to stage of disease and line of therapy, including assessment of treatment decisions. * Extensive evaluation of current chemotherapy regimens used, including detailed analysis of individual drug use by stage and therapy line. * Determination of future trends based on current treatment patterns, medical opinion, and analysis of the development pipeline for colorectal cancer. Report Highlights: Distinct roles for chemotherapy are emerging in colorectal cancer treatment: palliative chemotherapy alone and adjuvant or neoadjuvant use with surgery, each with unique opportunities. Irinotecan/oxaliplatin regimens are becoming the new gold standard therapies for advanced disease and will see dramatically increased use in early-stage disease. Increased use of screening will shift diagnosis toward early-stage disease, consequently decreasing the proportion of patients with metastatic disease. Reasons to Purchase: * Appreciate how the patient segmentation by stage of disease will change through more effective screening, altering treatment patterns * Discover the potential of the emerging areas of chemotherapy, e.g. adjuvant/neoadjuvant use with surgery, and how to best exploit them * Understand how the penetration of novel drugs such as irinotecan and oxaliplatin into standard treatment differs between markets and why * Identify key areas of unmet need, based on physician/opinion leader interviews * Assess who the key decision-makers are in different markets and what obstacles need to be surmounted for maximum product uptake Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a274 |
|
|
